Sage Therapeutics (SAGE) Q2 2024 earnings summary

Executive summary

• ZURZUVAE, the first and only oral FDA-approved product for postpartum depression (PPD), showed strong Q2 2024 performance, with prescriptions and shipments nearly doubling from Q1 and over 2,000 prescriptions written, driven by OB-GYN adoption and broad payor coverage.

• ZULRESSO revenue declined due to ZURZUVAE's launch, while the company discontinued SAGE-324 development in essential tremor after negative Phase 2 results.

• Dalzanemdor (SAGE-718) development in Huntington's and Alzheimer's continues, with topline data from key studies expected late 2024 and a primary endpoint change in the DIMENSION study to SDMT.

• FDA issued a complete response letter for zuranolone in major depressive disorder (MDD); additional trials required for approval in MDD.

• The company maintains a strong financial foundation, with cash and marketable securities totaling approximately $647 million at quarter end.

Financial highlights

• Q2 2024 total revenue was $8.7 million, up from $2.5 million in Q2 2023, driven by ZURZUVAE collaboration revenue of $7.4 million.

• Net loss for Q2 2024 was $102.9 million, improved from $160.3 million in Q2 2023.

• R&D expenses were $62.6 million and SG&A expenses were $56 million in Q2 2024, both down year-over-year due to restructuring.

• ZULRESSO net revenue was $0.6 million in Q2 2024, down from $2.5 million in Q2 2023.

• Cash, cash equivalents, and marketable securities totaled $647 million as of June 30, 2024.

Outlook and guidance

• Existing cash and anticipated revenues expected to fund operations into 2026.

• Topline data from dalzanemdor DIMENSION and LIGHTWAVE studies expected in late 2024.

• Strategic sales force expansion planned for early Q4 to accelerate ZURZUVAE uptake.

• Operating expenses projected to decrease in 2024 due to prior restructuring, but significant costs will continue for ZURZUVAE commercialization and dalzanemdor trials.

• No further milestone payments anticipated in 2024; revenue growth dependent on ZURZUVAE uptake.